Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single centre phase II, randomised placebo controlled cross over study to examine the effect of anamorelin on cancer cachexia in patients with mesothelioma

Next Previous
Trial Profile

A single centre phase II, randomised placebo controlled cross over study to examine the effect of anamorelin on cancer cachexia in patients with mesothelioma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anamorelin (Primary)
  • Indications Cachexia
  • Focus Therapeutic Use
  • Acronyms ANTHEM

Most Recent Events

  • 20 Jan 2022 Actual date of last participant enrolled is 22/09/2020 according to Australian New Zealand Clinical Trials Registry record.
  • 20 Jan 2022 Planned End Date changed from 3 May 2021 to 31 Aug 2021.
  • 20 Jan 2022 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top